v3.26.1
LICENSE, COLLABORATION AND OTHER REVENUE (Tables)
 3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenues Recognized from License, Collaboration and Other Significant Agreements
The Company recognized the following revenue from its license, collaboration and other revenue agreements (in thousands):
 Three Months Ended March 31,
EntityDescription20262025
Medice
License and royalties related to the sale of Vafseo in the EU
$32 $7 
TPCLicense and Product Supply of Vafseo in Japan341 369 
JT and Torii License and royalties related to the sale of Riona in Japan1,179 1,169 
Total license and other revenue $1,552 $1,545 
Schedule of Changes in Contract Assets and Liabilities
The following tables present changes in the Company’s contract assets and liabilities related to the Company's sales to its AG Distributor (in thousands):
Three Months Ended March 31, 2026
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable$194 $— $— $194 
Contract liabilities:
Deferred revenue$2,681 $4,826 $(3,011)$4,496 
Three Months Ended March 31, 2025
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable$— $1,241 $— $1,241 
Contract liabilities:
Deferred revenue$— $1,241 $— $1,241 
The Company recognized the following revenues related to the Company's sales to its AG Distributor as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands): 
Three Months Ended March 31,
Revenue Recognized in the Period:20262025
Deferred revenue — beginning of the period
$3,011 $— 
The following tables present changes in the Company’s contract assets and liabilities related to license and other revenue (in thousands):
Three Months Ended March 31, 2026
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract asset:    
Accounts receivable(1)
$2,391 $1,552 $(2,282)$1,661 
Three Months Ended March 31, 2025
Balance at
Beginning of
Period		AdditionsDeductionsBalance
at End
of Period
Contract assets:
Accounts receivable(1)
$2,010 $1,545 $(1,989)$1,566 
(1) Excludes accounts receivable related to amounts due to the Company from product sales of Auryxia and Vafseo which are included in the accompanying unaudited condensed consolidated balance sheets as of March 31, 2026 and 2025.
Schedule of Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities
The Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands): 
Three Months Ended March 31,
Revenue Recognized in the Period:20262025
Deferred revenue — beginning of the period$— $—